UK Retail Sales Rebound; Softcat Finalizes Fundraising

{
  "signal_id": "4800b67d-557f-78d3-92d6-9d6c35c55a28",
  "signal_type": "news",
  "signal_subtype": "is_developing",
  "detected_at": "2026-09-18T07:00:38+00:00",
  "company": {
    "name": "AstraZeneca",
    "domain": "astrazeneca.com"
  },
  "data": {
    "url": "https://ch.zonebourse.com/actualite-bourse/rebond-des-ventes-au-detail-au-royaume-uni-softcat-finalise-sa-levee-de-fonds-ce785adad889f422",
    "title": "UK Retail Sales Rebound; Softcat Finalizes Fundraising - Zonebourse Switzerland",
    "excerpt": "Published on 18/09/2026 at 09:00 Contact us for any correction request (Alliance News) - UK retail sales rebounded in August, exceeding market expectations. AstraZeneca's efzimfotase alfa received 'Priority Review' designation in the US for the treatment of hypophosphatasia, while Softcat raised 354 million GBP to help fund its acquisition of GDT for 1.05 billion USD. Here's what you need to know before London markets open: ---------- MARKETS ---------- FTSE 100: expected down 0.1% at 10,806.94 GBP: up at 1.3373 USD (1.3356 USD at previous London equities close) ---------- ECONOMY ---------- UK retail sales rebounded in August, exceeding forecasts, according to the Office for National Statistics (ONS). Retail sales volumes increased by 0.5% month-on-month, erasing a 0.5% decline in July and surpassing the 0.2% decrease expected by FXStreet. June's increase was revised downwards, to 0.6% from 0.7% initially. The ONS indicates that non-store retailers partially recovered after July's decline, a month during which sales suffered from anticipated promotions in June, while department store sales improved following stock availability issues. Year-on-year, retail sales volumes increased by 2.4% in August. Over the three months to August, volumes grew by 0.9% compared to the previous three-month period and show an annual increase of 2.4%, driven by non-store sales and food...",
    "product": "efzimfotase alfa",
    "summary": "AstraZeneca's efzimfotase alfa, developed by its subsidiary Alexion, received 'Priority Review' designation in the US for treating hypophosphatasia, with a regulatory decision expected in the first half of 2027.",
    "location": "United States",
    "planning": true,
    "image_url": "https://ch.zonebourse.com/images/twitter_ZB_fdblanc.png",
    "confidence": 0.9,
    "product_data": {
      "name": "efzimfotase alfa",
      "full_text": "efzimfotase alfa",
      "fuzzy_match": false
    },
    "product_tags": [
      "medical",
      "general_technology"
    ],
    "published_at": "2026-09-18T07:00:38Z",
    "location_data": [
      {
        "region": "Northern America",
        "country": "United States",
        "continent": "Americas",
        "fuzzy_match": false
      }
    ],
    "article_sentence": "AstraZeneca announces that the US Food & Drug Administration (FDA) has accepted and granted 'Priority Review' designation to Alexion's Biologics License Application for efzimfotase alfa.",
    "related_company_name": "Alexion",
    "related_company_domain": "alexion.com"
  }
}

curl https://signals.autobound.ai/v1/signals/4800b67d-557f-78d3-92d6-9d6c35c55a28 \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"astrazeneca.com","limit":20}'